Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Urologic Diseases 1Shock 1Rheumatic Diseases 1Renal Insufficiency 1Nervous System Diseases 1Kidney Diseases 1Infections 1Hematologic Diseases 1Heart Failure 1Gastrointestinal Diseases 1Critical Illness 1Cardiovascular Diseases 1Asthma 1Arrhythmias, Cardiac 1

Interventions

pembrolizumab 1270Specimen Handling 870Carboplatin 831Magnetic Resonance Spectroscopy 808Cyclophosphamide 802Cisplatin 728Nivolumab 658Paclitaxel 631Radiotherapy 573Gemcitabine 572Biopsy 529Bevacizumab 475Dexamethasone 440fludarabine 407Docetaxel 378venetoclax 370Oxaliplatin 365Capecitabine 356Fluorouracil 354atezolizumab 341durvalumab 334Rituximab 332Doxorubicin 316Radiosurgery 309Pemetrexed 305Drug Therapy 302Ipilimumab 294Standard of Care 293Etoposide 285Radiation 279

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Health Information Exchange × 1 year × Clear all
NCT05443321 2026-01-23

Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes

Brigham and Women's Hospital

Phase NA Enrolling by invitation
1,006 enrolled
GastrointestinalGenitourinary

Arrhythmias, Cardiac, Asthma, Cardiovascular Diseases, Gastrointestinal Diseases, Heart Failure, Hematologic Diseases, Infections, Kidney Diseases, Nervous System Diseases, Rheumatic Diseases, Shock, Urologic Diseases, Critical Illness, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡